Excellent
Mostly Aligned
Patient Risk:
Low
Summary
All three evaluated claims (embryo-fetal toxicity/contraindicated pregnancy with REMS requirements, hematologic toxicity with CBC monitoring and dose modifications, and increased venous/arterial thromboembolism with thromboprophylaxis and symptom monitoring) are supported by the provided FDA label sections.
Category Scores
Accurate Statements
REVLIMID has embryo-fetal toxicity and is contraindicated during pregnancy; REMS pregnancy prevention requirements apply.
Supported by Section 4.1 (pregnancy contraindication), Boxed Warning (embryo-fetal toxicity), Section 5.1 (pregnancy avoidance/testing/contraception requirements) and Section 5.2 (available only through Lenalidomide REMS program).
REVLIMID can cause hematologic toxicity including neutropenia and thrombocytopenia; CBC monitoring and potential dose interruption/reduction are required.
Supported by Section 5.3 (neutropenia and thrombocytopenia; monitor CBC; dose interruption and/or dose reduction may be required).
REVLIMID increases venous and arterial thromboembolism risk; thromboprophylaxis is recommended and patients should be monitored for symptoms.
Supported by Section 5.4 (increased VTE/ATE risk; thromboprophylaxis recommended; instruct patients to report thrombotic signs/symptoms).
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The audited claims accurately reflect label-supported embryo-fetal, hematologic, and thromboembolism risks and associated monitoring/management recommendations; no label-inconsistent statements were detected.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement